Silence Therapeutics (SLN) Non-Current Deffered Revenue (2019 - 2025)
Historic Non-Current Deffered Revenue for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to $55.3 million.
- Silence Therapeutics' Non-Current Deffered Revenue changed N/A to $55.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.3 million, marking a year-over-year change of. This contributed to the annual value of $51.8 million for FY2024, which is 3094.76% down from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' Non-Current Deffered Revenue is $55.3 million.
- In the past 5 years, Silence Therapeutics' Non-Current Deffered Revenue registered a high of $97.7 million during Q4 2021, and its lowest value of $51.8 million during Q4 2024.
- Moreover, its 5-year median value for Non-Current Deffered Revenue was $56.3 million (2025), whereas its average is $66.0 million.
- Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 4417.32% in 2021, then tumbled by 2916.76% in 2024.
- Silence Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $97.7 million in 2021, then decreased by 23.81% to $74.5 million in 2022, then decreased by 1.81% to $73.1 million in 2023, then decreased by 29.17% to $51.8 million in 2024, then rose by 6.68% to $55.3 million in 2025.
- Its Non-Current Deffered Revenue was $55.3 million in Q3 2025, compared to $56.3 million in Q2 2025 and $53.3 million in Q1 2025.